210 related articles for article (PubMed ID: 36361531)
41. The Tumorigenic Effect of Sphingosine Kinase 1 and Its Potential Therapeutic Target.
Wang X; Sun Y; Peng X; Naqvi SMAS; Yang Y; Zhang J; Chen M; Chen Y; Chen H; Yan H; Wei G; Hong P; Lu Y
Cancer Control; 2020; 27(1):1073274820976664. PubMed ID: 33317322
[TBL] [Abstract][Full Text] [Related]
42. SphK1 confers resistance to apoptosis in gastric cancer cells by downregulating Bim via stimulating Akt/FoxO3a signaling.
Xiong H; Wang J; Guan H; Wu J; Xu R; Wang M; Rong X; Huang K; Huang J; Liao Q; Fu Y; Yuan J
Oncol Rep; 2014 Oct; 32(4):1369-73. PubMed ID: 25109605
[TBL] [Abstract][Full Text] [Related]
43. Metastatic triple-negative breast cancer is dependent on SphKs/S1P signaling for growth and survival.
Maiti A; Takabe K; Hait NC
Cell Signal; 2017 Apr; 32():85-92. PubMed ID: 28108260
[TBL] [Abstract][Full Text] [Related]
44. Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia.
Powell JA; Lewis AC; Zhu W; Toubia J; Pitman MR; Wallington-Beddoe CT; Moretti PA; Iarossi D; Samaraweera SE; Cummings N; Ramshaw HS; Thomas D; Wei AH; Lopez AF; D'Andrea RJ; Lewis ID; Pitson SM
Blood; 2017 Feb; 129(6):771-782. PubMed ID: 27956387
[TBL] [Abstract][Full Text] [Related]
45. ABCC1-Exported Sphingosine-1-phosphate, Produced by Sphingosine Kinase 1, Shortens Survival of Mice and Patients with Breast Cancer.
Yamada A; Nagahashi M; Aoyagi T; Huang WC; Lima S; Hait NC; Maiti A; Kida K; Terracina KP; Miyazaki H; Ishikawa T; Endo I; Waters MR; Qi Q; Yan L; Milstien S; Spiegel S; Takabe K
Mol Cancer Res; 2018 Jun; 16(6):1059-1070. PubMed ID: 29523764
[TBL] [Abstract][Full Text] [Related]
46. Targeting SPHK1/S1PR3-regulated S-1-P metabolic disorder triggers autophagic cell death in pulmonary lymphangiomyomatosis (LAM).
Li F; Zhang Y; Lin Z; Yan L; Liu Q; Li Y; Pei X; Feng Y; Han X; Yang J; Zheng F; Li T; Zhang Y; Fu Z; Shao D; Yu J; Li C
Cell Death Dis; 2022 Dec; 13(12):1065. PubMed ID: 36543771
[TBL] [Abstract][Full Text] [Related]
47. SphK1 promotes development of non‑small cell lung cancer through activation of STAT3.
Ma Y; Xing X; Kong R; Cheng C; Li S; Yang X; Li S; Zhao F; Sun L; Cao G
Int J Mol Med; 2021 Jan; 47(1):374-386. PubMed ID: 33236138
[TBL] [Abstract][Full Text] [Related]
48. The sphingosine kinase 1 and S1P1 axis specifically counteracts LPS-induced IL-12p70 production in immune cells of the spleen.
Schröder M; Richter C; Juan MH; Maltusch K; Giegold O; Quintini G; Pfeilschifter JM; Huwiler A; Radeke HH
Mol Immunol; 2011 May; 48(9-10):1139-48. PubMed ID: 21435724
[TBL] [Abstract][Full Text] [Related]
49. Sphingosine kinase 1 (SPHK1) is induced by transforming growth factor-beta and mediates TIMP-1 up-regulation.
Yamanaka M; Shegogue D; Pei H; Bu S; Bielawska A; Bielawski J; Pettus B; Hannun YA; Obeid L; Trojanowska M
J Biol Chem; 2004 Dec; 279(52):53994-4001. PubMed ID: 15485866
[TBL] [Abstract][Full Text] [Related]
50. Physcion 8-O-β-glucopyranoside exhibits anti-leukemic activity through targeting sphingolipid rheostat.
Han J; Zhao P; Shao W; Wang Z; Wang F; Sheng L
Pharmacol Rep; 2018 Oct; 70(5):853-862. PubMed ID: 30092415
[TBL] [Abstract][Full Text] [Related]
51. Targeting sphingosine kinase-1 to inhibit melanoma.
Madhunapantula SV; Hengst J; Gowda R; Fox TE; Yun JK; Robertson GP
Pigment Cell Melanoma Res; 2012 Mar; 25(2):259-74. PubMed ID: 22236408
[TBL] [Abstract][Full Text] [Related]
52. S1P/S1PR3 axis promotes aerobic glycolysis by YAP/c-MYC/PGAM1 axis in osteosarcoma.
Shen Y; Zhao S; Wang S; Pan X; Zhang Y; Xu J; Jiang Y; Li H; Zhang Q; Gao J; Yang Q; Zhou Y; Jiang S; Yang H; Zhang Z; Zhang R; Li J; Zhou D
EBioMedicine; 2019 Feb; 40():210-223. PubMed ID: 30587459
[TBL] [Abstract][Full Text] [Related]
53. Role of sphingosine kinase 1 and sphingosine-1-phosphate in CD40 signaling and IgE class switching.
Kim EY; Sturgill JL; Hait NC; Avni D; Valencia EC; Maceyka M; Lima S; Allegood J; Huang WC; Zhang S; Milstien S; Conrad D; Spiegel S
FASEB J; 2014 Oct; 28(10):4347-58. PubMed ID: 25002116
[TBL] [Abstract][Full Text] [Related]
54. Sphingosine kinase inhibitors decrease viability and induce cell death in natural killer-large granular lymphocyte leukemia.
LeBlanc FR; Liu X; Hengst J; Fox T; Calvert V; Petricoin EF; Yun J; Feith DJ; Loughran TP
Cancer Biol Ther; 2015; 16(12):1830-40. PubMed ID: 26252351
[TBL] [Abstract][Full Text] [Related]
55. Sphingosine Kinase 1 and Sphingosine-1-Phosphate Signaling in Colorectal Cancer.
Bao Y; Guo Y; Zhang C; Fan F; Yang W
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 28991193
[TBL] [Abstract][Full Text] [Related]
56. Relationship between Sphk1/S1P and microRNAs in human cancers.
Khoei SG; Sadeghi H; Samadi P; Najafi R; Saidijam M
Biotechnol Appl Biochem; 2021 Apr; 68(2):279-287. PubMed ID: 32275078
[TBL] [Abstract][Full Text] [Related]
57. [Role of SPHK1 regulates multi-drug resistance of small cell lung cancer
and its clinical significance].
Yang L; Hu H; Deng Y; Bai Y
Zhongguo Fei Ai Za Zhi; 2014 Nov; 17(11):769-77. PubMed ID: 25404266
[TBL] [Abstract][Full Text] [Related]
58. Loss of sphingosine kinase 1/S1P signaling impairs cell growth and survival of neurons and progenitor cells in the developing sensory ganglia.
Meng H; Yuan Y; Lee VM
PLoS One; 2011; 6(11):e27150. PubMed ID: 22096531
[TBL] [Abstract][Full Text] [Related]
59. Sphingosine kinase 1 is a potential therapeutic target for nasopharyngeal carcinoma.
Li W; Li J; Wang Y; Zhang K; Li N; Tian Z; Ni B; Wang H; Ruan Z
Oncotarget; 2016 Dec; 7(49):80586-80598. PubMed ID: 27811359
[TBL] [Abstract][Full Text] [Related]
60. Sirtuin 7 promotes non‑small cell lung cancer progression by facilitating G1/S phase and epithelial‑mesenchymal transition and activating AKT and ERK1/2 signaling.
Zhao Y; Ye X; Chen R; Gao Q; Zhao D; Ling C; Qian Y; Xu C; Tao M; Xie Y
Oncol Rep; 2020 Sep; 44(3):959-972. PubMed ID: 32705247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
